Darrel Cohen named CMO of cell therapy at Athenex

Repurposed drug has promising efficacy in shrinking NSCLC tumors

An FDA-approved drug used to treat multiple myeloma and lymphoma also shrank tumors in non-small cell lung cancer with KRAS mutations, a clinical trial led by UT Southwestern Harold C. Simmons Comprehensive Cancer Center researchers showed.

December 13, 2024

Vol.50 No.46

Drugs & Targets

Dewpoint Therapeutics and ConcertAI form drug development partnership

Dewpoint Therapeutics and ConcertAI announced the first phase of their Translational Oncology partnership, aligned around Dewpoint’s latest drug candidate, DPTX3186.

December 13, 2024

Vol.50 No.46

Clinical Roundup

Engineered HSV can trigger genetic chain reaction, rearrange HSV genes during co-infection

In preclinical work recently published in Nature Communications, Fred Hutchinson Cancer Center scientists used a genetic “chain reaction” to transform herpes simplex virus DNA during an HSV infection.

November 15, 2024

Vol.50 No.43

Clinical Trials & Tribulations

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC

At its most recent meeting, the FDA Oncologic Drugs Advisory Committee focused on perioperative clinical trials, which the agency defined as neoadjuvant phase followed by surgery and continuing with adjuvant treatment using the same experimental agent (The Cancer Letter, July 26, 2024).

MD Anderson and industry partners to conduct T cell studies on the International Space Station

The University of Texas MD Anderson Cancer Center and collaborators are initiating a research project that will send T cells to the International Space Station to study the effects of prolonged microgravity on cell differentiation, activation, memory, and exhaustion.

August 02, 2024

Vol.50 No.31

Regulatory News

ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.

July 26, 2024

Vol.50 No.30

By Jacquelyn Cobb and Paul Goldberg

Darrel Cohen named CMO of cell therapy at Athenex

YOU MAY BE INTERESTED IN

Repurposed drug has promising efficacy in shrinking NSCLC tumors

Dewpoint Therapeutics and ConcertAI form drug development partnership

Engineered HSV can trigger genetic chain reaction, rearrange HSV genes during co-infection

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC

MD Anderson and industry partners to conduct T cell studies on the International Space Station

ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

Renew today!

Subscriber content

Never miss an issue!

Login

Darrel Cohen named CMO of cell therapy at Athenex

YOU MAY BE INTERESTED IN

Repurposed drug has promising efficacy in shrinking NSCLC tumors

Dewpoint Therapeutics and ConcertAI form drug development partnership

Engineered HSV can trigger genetic chain reaction, rearrange HSV genes during co-infection

Of adaptive and factorial designsA biostatistician’s interpretation of last week’s ODAC

MD Anderson and industry partners to conduct T cell studies on the International Space Station

ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

Never miss an issue!

Login

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC